ArticleFrontiers in bioengineering and biotechnology2026
Nanocomposites of Opuntia ficus-indica mucilage-mediated selenium nanoparticles and nanochitosan as antidiabetic candidates in streptozocin-induced diabetic rats.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetes is considered a serious chronic disease that carries a high risk of significant complications. Recently, the utilization of natural hypoglycemic plants has been increasing for the management of diabetes due to their biosafety, low side effects, and economical features. Methods: Fruits peel mucilage (FM) was extracted from OFI fruit for the green synthesis of selenium nanoparticles (SeNPs), which were then encapsulated with chitosan (Ch) to generate nanocomposites (Ch/FM/SeNPs). This study was carried out to evaluate the antidiabetic activity of nanocomposites (Ch/FM/SeNPs) against streptozotocin (STZ)-induced diabetic rats. Accordingly, rats were divided into six groups, namely, normal control (GI), diabetic control (GII), treatment groups (GIII, GIV, and GV) administered nanocomposite powder (Ch/FM/SeNPs) with concentrations 0.1, 0.2, and 0.3 mg/kg, respectively, and (GVI) received glibenclamide at a dose of 5 mg/kg for 28 days. At the end of the treatment, the rats were subjected to analysis including body weight, blood glucose level, lipid profile, and hepatic and renal function tests. Results: The nanocomposite (Ch/FM/SeNPs) had an average particle size (PS) of 81.18 nm and a positive charge (+30.11 mV), with an equivalent ratio of Ch and FM/SeNPs (1:1). The average particle size of FM/SeNPs was 6.34 nm with a negative charge (-25.93 mV). The morphological characteristics indicated semi-spherical shapes of the nanocomposites (NCs) and stabilization and homogenous distribution of SeNPs within the polymer nanocomposites. The results indicated that treatment of diabetic rats with nanocomposite powder (Ch/FM/SeNPs) at a concentration of 0.3 mg/kg resulted in significant increases in body weight, along with significant reductions in blood glucose levels and improvement in biological parameters, lipid profile, and hepatic and renal function. Conclusion: Promisingly, the nanocomposite (Ch/FM/SeNPs) can be used as a hypoglycemic compound; therefore, it could be recommended for the development of antidiabetic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.